Ocular drug delivery system requires a series of specified characteristics ... the
point of view of production and sterilization, nanoemulsions are relatively simple
...
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
6.1. Introduction Ocular drug delivery system requires a series of specified characteristics according to the physiological structure of the eye. Eye is a unique and challenging organ for therapeutic drug delivery on to the surface as well as in the interior part of ocular structure. Many of its anatomical and physiological makeup interfere with the fate of the administered drug and bioactives. Tears permanently wash the surface of the eye and exert an anti-infectious activity by the lysozyme and immunoglobulins they contain. In addition, drug may bind to tear proteins and conjunctival mucin. To treat the local ophthalmic diseases, liquid eye drop is the most desirable dosage form when considering convenience of administration and clinical compliance of the patients. However, conventional eye drops, most of which present in the drug solution form, usually have quite a limited therapeutic efficiency due to the low bioavailability. In clinical use of eye drops, frequent instillations are often required to get the expected therapeutic effect, and this leads to rising inconvenience and adverse effects. Typically, less than 5% of the drug applied penetrates the cornea/sclera and reaches the intraocular tissue, with the major fraction of the dose applied often absorbed systemically through the conjunctiva and nasolacrimal duct. On the other hand, corneal and conjunctival epithelia of human eye, along with the tear film, construct a compact barrier preventing the drug absorption into the intraocular area resulting into low bioavailabilty and undesirable systemic side effects (Lang., 1995). So, drug delivery in ocular therapeutics is a challenging concern and is a subject of interest to scientists working in the multidisciplinary areas pertaining to the eye (Bourlais et al., 1998). In general, the major problem in ocular therapeutics is to maintain an effective drug concentration in ocular tissue or at the site of action for a significant period of time, in order to achieve the expected therapeutic response. Ophthalmic drug delivery, probably more than any other route of administration, may get benefit from the uniqueness of Nanoapproaches -based drug delivery (Sahoo et al., 2003).
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 130
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
The use of nanocarriers provides attractive prospect for topical ocular drug delivery, mainly because of their capacity to protect the encapsulated molecule, along with its facilitated transport to the different compartments of the eye (Losa et al., 1993; Kayseri et al., 2005). Various nano systems were adopted for the corneal retention and bioavailabilty enhancement colloidal systems such as liposomes (Pleyer et al., 1993; Bochot et al., 1998) and nanoparticles (Losa et al., 1991; De Campos et al., 2004) and nanocapsules (Losa et al., 1993; De Campos et al., 2003) and nanoemulsions. Nanoemulsions (NEs) are defined as the dispersions of water and oil in the presence of combination of surfactant and co-surfactant (Smix) in a manner to reduce interfacial tension. On the basis of nature of dispersion and disperse phase, NEs were classified as: o/w, w/o & bi-continous type. These systems are usually characterized by clear appearance, higher thermodynamic stability, small droplet size (< 200 nm), high drug solubility, and drug reservoir for lipophilic and hydrophilic drugs (Ansari et al., 2008). Nanoemulsions, particularly, oil/water nanoemulsions have received the greatest attention because of their small size may provide a promising alternative. From the point of view of production and sterilization, nanoemulsions are relatively simple and inexpensive because they are thermodynamically stable. Nanoemulsions are also used to formulate poorly water-soluble drugs since their structure allows solubilization of lipophilic drugs in the oil phase. Moreover, nanoemulsions achieve sustained release of a drug applied to the cornea and higher penetration into the deeper layers of the ocular structure and the aqueous humor than the native drug. These systems offer additional advantages including: low viscosity, a greater ability as drug delivery vehicles and increased properties as absorption promoters. Earlier successful nanoemulsions of pilocarpine,timolol maleate,and chloramphenicol have been formulated (Akhter et al, 2011). Extensive investigations carried out over the last decade support the view that cyclosporin A (CYA), a hydrophobic peptide with powerful immunosuppressive action, is effective in the treatment of extraocular
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 131
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
disorders such as keratoconjunctivitis sicca and dry eye disease and for the prevention of corneal allograft rejection (Power et al., 1993). However, the poor aqueous solubility of CYA (6.6_g/ml) is a limiting factor for the formulation of solutions intended for ocular administration (Lallemand et al., 2003). Despite the evidence that the target sites for the treatment of these diseases are the cornea and conjunctiva (Gunduz and O zdemir, 1994; Acheampong et al., 1999), the CYA delivery systems investigated so far (i.e., oils, emulsions, collagen shields, liposomes and nanocapsules) have not been successful. Collagen shields were found to provide a sustained delivery of CYA to the surface of the eye. However, the use of such a system is limited by the ocular irritation and blurring of vision that it causes (Dua et al., 1996). The most popular oil-based vehicles have serious limitations that include the slow partition rate of CYA into the corneal epithelium (Acheampong et al., 1999), the intraocular and/or systemic absorption of CYA (Foets et al., 1985; Bellot et al., 1992), and the local side effects associated with the use of oils (symptoms of irritation, blurred vision, itching, transient epithelial keratitis and toxic effects at corneal level (Kaswan et al., 1989). In 2002, a CYA 0.05% lipid emulsion (RestasisTM, Allergan, Irvine, USA) received FDA approval as the first and only therapy for patients with keratoconjunctivitis sicca, whose lack of tear production is presumed to be due to ocular inflammation. However, as the corneal concentration achieved with dosing four times a day is insufficient to prevent immunologic graft reactions, RestasisTM is not effective in preventing rejection after corneal allograft (Price and Price, 2006). Previous attempt by Calvo et al have been carried out to improve the ocular penetration of CYA by developing CYA loaded poly-o-caprolactone nanocapsules. These new delivery systems were efficient at improving the transcorneal transport of CYA while reducing systemic absorption but they did not provide significant CYA at the ocular mucosa for extended periods of time (Calvo et al., 1996). However polymeric nanosystem release the entrapped drug in controlled fashion over extended period
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 132
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
of time but in such cases we can’t get the therapeutic concentration at a time and sustained the same for e longer period. So, particularly in case of infectious and immunological diseases of eye, it is desirable that the delivery system should release the bioactive molecule fast the elicit the immunosuppressive action. Moreover, improving the tissue penetration and ocular retention further improve the management of diseases condition with a small dosing regimen. Consequently, the design of a system with improved drug delivery properties to the ocular surface would be a promising step towards the management of external ocular diseases, such as keratoconjunctivitis sicca or dry eye disease. Taking into account this information and also the fact that the cornea and conjunctiva have a negative charge, it was thought that the use of mucoadhesive polymers which might interact intimately with these extra-ocular structures would increase the concentration and residence time of the associated drug. Mucoadhesive nanoemulsion system as a carrier for CYA, may play a key role and fulfilled the desirable characteristic required for effective CYA delivery. Among the mucoadhesive polymers investigated until now, the cationic polymer chitosan (CH) has attracted a great deal of attention because of its unique properties, such as acceptable biocompatibility and biodegradability (Knapczyk et al., 1989; Hirano et al., 1990) and ability to enhance the paracellular transport of drugs (Artursson et al., 1994). Moreover, CH has recently been proposed as a material with a good potential for ocular drug delivery. More specifically, CH solutions were found to prolong the corneal residence time of antibiotic drugs (Felt et al., 1999), whereas CH coated nanocapsules were more efficient at enhancing the intraocular penetration of some specific drugs (Calvo et al., 1997a; Genta et al., 1997). More recent work has shown the interaction and prolonged residence time of CH nanoparticles at the ocular mucosa after their topical administration to rabbits (De Campos et al., 2009). Based on these consideration, chitosan based mucoadhesive nanoemulsion encapsulate with 3 % w/v of CYA were developed and characterised for in-vitro
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 133
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
performance. In-vivo study to validate the corneal retention (by γ-scintigraphy technique) and biodistribution by UPLC/Q-TOF-MS/MS method were also evaluated. 6.2. Materials and methods 6.2.1. Chemicals Cyclosporin A (CYA) was kindly gifted by Ranbaxy Laboratories Ltd. (Gurgaon, Haryana, India). Chitosan (CH, deacetylation degree >80%) was received as a gift sample from India Sea Foods (India). Tween 80, tween 20, oleic acid, isopropyl merestate (IPM), olive oil, tricetin, castor oil, triton X 100, poly ethylene glycol (PEG 200 & PEG 400), propylene glycol, span 20, Transcutol P were purchased from CDH, Delhi , India. Labrafil M, labrafac, labrosol, and Lauroglycol 90 were obtained from Gattefose, France. Sefsol 218 was gifted from Nikko chemicals (Japan). Milli-Q water was produced in the laboratory by Milli-Q water purification system (MA, USA), whereas, LCMS grade acetonitrile was obtained from Qualigens Fine Chemicals (Mumbai, India). All other chemicals and reagents used were of analytical grade and were purchased from Merck Ltd. (Mumbai, India). 6.3. Methods 6.3.1. UPLC/Q-TOF-MS/MS Quantification Method for CYCLOSPORIN A UPLC was performed with a Waters Acquity™ UPLC system (Serial No# F09 UPB 920M; Model Code# UPB; Waters, MA, USA) equipped with a binary solvent delivery system, an auto-sampler, column manager and a tuneable MS detector (Serial No# JAA 272; Synapt; Waters, Manchester, UK). Chromatographic separation was performed on an Acquity UPLC BEH C18 (100mm×2.1mm, 1.7μm) column at 35±2ºC. The mobile phase consisting of Acetonitrile, Water and Formic Acid ( 0.1% v/v) in the ratio of 45:45:10 with a flow rate of 0.5 ml / min was employed for a total run time of 3 min. Data acquisition, data handling and instrument control were performed by Empower Software v1.0.
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 134
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Mass spectrometry was performed on a Waters Q-TOF Premier (Micromass MS Technologies, Manchester, UK) mass spectrometer. The nebulisation gas was set to 500 L/h, the cone gas was set to 50 L h-1 and the source temperature was set to 100ºC. The capillary voltage and sample cone voltage were set to 3.0 KV and 40 V, respectively. The Q-TOF Premier™ was operated in V mode with a resolution over 8500 mass with 1.0 min scan time, and 0.02 s inter-scan delay. The accurate mass and composition for the precursor ions and for the fragment ions were calculated using the MassLynx V 4.1 software incorporated in the instrument. Argon was employed as the collision gas at a pressure of 5.3 х 10-5 torr. Quantitation was performed using Synapt mass spectrometer (Q-TOF) of the transitions of m/z 1225.1764→1113.0751 for with a scan time of 1.0 min, and 0.02 s inter-scan per transition. The optimum values for compound-dependent parameters like trap collision energy and transfer collision energy were set to 13.2 and 80 eV, respectively for fragmentation. 6.3.2. Preparation of nanoemulsion formulations 6.3.2.1. Screening & optimization of oil, surfactant and co-surfactants The most important criterion for screening of components is the solubility of poorly soluble drug in oils, surfactants and cosurfactants (Akhter et al., 2008). The solubility of Cyclosporin was determined in different oils viz. oleic acid, isopropyl myristate (IPM), olive oil, triacetin, jojoba oil, castor oil, safsol, labrafac, babchi oil and soyabean oil. 2 ml of different oils was taken in small vials and excess amount of the drug was added. The vials were tightly stoppered and were continuously stirred for 72 hours at 37 ± 0.5o C and samples were centrifuged at 10,000 rpm for 10 min. The suspension was filtered through a membrane filter (0.45 μm) and after appropriate dilution with methanol; solubility was determined by UPLC-MS/MS. Similar method was adopted for solubility determination of CYA in surfactant and cosurfactant. On the basis of solubility studies, oleic acid was
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 135
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
selected as the oil phase. Due to slight difference in the solubility profile of drug in different surfactants and cosurfactants, phase behaviors were studied by taking different surfactants and cosurfactants. Total eight combinations of surfactant and cosurfactants were prepared. The combination giving the larger nanoemulsion region was selected for the further study. For optimization of surfactant, initially cosurfactant (Transcutol P) was kept constant and different surfactant (Tween 20, 80, Cremophore EL and labrasol) in 1:1 ratio with cosurfactant was used and the mixture is called as Smix. For each phase diagram, oil and specific Smix were mixed well in different ratios. Sixteen different combinations of oil and Smix (1:9, 1:8, 1:7, 1:6, 1:5 1:4, 1:3.5, 1:3, 3:7, 1:2, 4:6, 5:5, 6:4, 7:3, 8:2 and 9:1) were made for phase diagram construction. The phase diagram was developed by aqueous titration method. For the optimization of cosurfactant, Tween 20 and cremophore EL were taken as surfactants. Aqueous titrations were performed by using different cosurfactants (Transcutol P, PEG 200, PEG 400 and propylene glycol). The ratio of surfactant to cosurfactant (Smix ratio) was kept constant (1:1 v/v) while oil to Smix ratio was taken 1:9 v/v. 6.3.2.2. Method of Preparation of nanoemulsion After optimization of oil, surfactant and cosurfactant, nanoemulsion formulations were developed by using oleic acid as oily phase, tween 20 and cremophore EL as surfactants and Transcutol P as cosurfactant. For each phase diagram, Smix ratios 1:0, 1:1, 1:2, 2:1, 3:1, 1:3, 4:1, 1:4 was prepared. Oil and specific Smix were mixed well in different ratios. Sixteen different combinations of oil and Smix (1:9, 1:8, 1:7, 1:6, 1:5 1:4, 1:3.5, 1:3, 3:7, 1:2, 4:6, 5:5, 6:4, 7:3, 8:2 and 9:1) were made for phase diagram construction. For each Smix ratio separate phase diagram was constructed. 6.3.2.3. Thermodynamic stability testing of drug loaded nanoemulsions To evaluate the stability, CYA loaded nanoemulsions were subjected to thermodynamic stability testing, which comprises of heating cooling cycle, freeze thaw cycle and
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 136
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
centrifugation test. Physical stability was continuously monitored throughout the experiment. Various aspects like phase separation, turbidity etc. at room temperature were observed (Akhter et al., 2008). 6.3.2.4. Freeze thaw cycle Selected nanoemulsions were kept in deep freezer (at -20oC) for 24h. After 24h the nanoemulsions were removed and kept at room temperature. The thermodynamically stable nanoemulsions returned to their original form within 2-3 minutes. 2-3 such cycles were repeated. 6.3.2.5. Centrifugation studies Nanoemulsions after freeze thaw cycle were subjected to centrifugation studies where they were made to undergo centrifugation for 30 minutes at 5,000 rpm in a centrifuge. The stable formulations did not show any phase separation or turbidity. 6.3.2.6. Heating cooling cycle Nanoemulsions were kept at 37±0.5 o C for 24 hrs. After that the nanoemulsions were kept at room temperature. The stable nanoemulsion should not show any sign of turbidity, cracking, creaming during the entire cycle. 6.3.3. Preparation of mucoadhesive chitosan solutions and assessment of mucoadhesive strength Different concentrations of chitosan solutions were prepared in the range of 0.1 to 1.0 % w/v in 0.2 % glacial acetic acid solution. The prepared solutions were evaluated for the mucoadhesive strength using TA.XTPlus Texture analyzer (Stable Micro Systems, Surrey, UK). The double-sided tape was placed on the tip of load cell and formulation was placed on excised goat cornea. Cornea with the formulation was then placed beneath the load cell and force (0.08 N) was applied by the load cell for 200 s. After this the load cell was pulled back
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 137
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
and force required to detach the particles from the cornea (by double sided tape) was determined as the mucoadhesive strength. 6.3.4. Characterization of nanoemulsions 6.3.4.1. Particle size distribution and zeta potential Globule size of oil droplet in NE was determined by photon correlation spectroscopy that analyzes the fluctuations in light scattering due to Brownian motion of the particles using a Zetasizer (Nano-ZS, Malvern Instruments, UK). The formulation (0.1 mL) was dispersed in 50 mL of water in a volumetric flask, mixed thoroughly with vigorous shaking, and light scattering was monitored at 25°C at a 90°angle. Whereas zeta potential was measured using a disposable zeta cuvette. For each sample, the mean diameter/zeta potential ± standard deviation of six determinations was calculated applying multimodal analysis. 6.3.4.2. Transmission electron microscopy (TEM) Morphology of the NE was studied using TEM (Morgagni 268D SEI, USA) operating at 200 KV and of a 0.18 nm capable of point to point resolution. Combination of bright field imaging at increasing magnification and of diffraction modes was used to reveal the form and size of the microemulsion. In order to perform the TEM observations, the diluted microemulsion was deposited on the holey film grid and observed after drying. 6.3.4.3. Viscosity determination The viscosity of the NEs was determined using Brookfield DV III ultra V6.0 RV cone and plate rheometer (Brookfield Engineering Laboratories, Inc., Middleboro, MA) using spindle # CPE40 at 25 ± 0.5 °C. The software used for the calculations was Rheocalc V2.6. 6.3.4.4. Refractive index and pH measurement Refractive index of microemulsions was determined using an Abbes type refractometer (Nirmal International, New Delhi, India). The apparent pH of the formulation was measured by pH meter (AccumentAB 15, Fisher scientific, USA) in triplicate at 25 ± 1ºC.
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 138
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
6.3.4.5. Preparation of chitosan mucoadhesive nanoemulsion Selected nanoemulsion formulation was imparted with mucoadhesive characteristics by using optimised chitosan solutions. In brief, the selected formulations in their optimised Smix ratio and oil to Smix ratio were titrated against the chitosan solution (1%w/v in 0.5 % v/v of glacial acetic solution). The developed mucoadhesive nanoemulsions were further characterized for particle size and zeta potential. 6.3.4.6. In vitro Release Study In vitro release studies were performed using standard Franz diffusion cells (FDC-6, LOGAN Instrument Corp., Somerset, NJ, USA). The diffusion area was 0.75 cm2 and receptor volume was 5.0 mL.
Receptor chambers were filled with 5 ml of PBS (pH 7.4; osmolality 297
mOSm/kg) and constantly stirred by small magnetic bars. The receptor fluid was stirred with a magnetic rotor at a speed of 600 rpm and the temperature was maintained at 35 ± 0.5°C in order to mimic the ocular surface temperature. Donor and receptor chambers were separated by means of activated dialysis membrane bag (molecular weight cut off 12,000 Da). One milliliters of each formulation were loaded into the donor compartment before occluding the chamber with Parafilm. Samples were withdrawn at regular intervals (0.025, 0.5, 1, 2 4,8 and 12 hr), filtered through 0.45-µm membrane filter and analyzed for drug content by UPLC/QTOF-MS/MS. 6.3.4.7. In-vivo study Ocular retention and biodistribution study of CYA in cornea, conjunctiva, aqueous humor and blood were carried out on New Zealand Albino rabbits (2.25±0.25 kg). The study was carried out under the guidelines of CPCSEA (Committee for the Purpose of Control and Supervision of Experiments on Animals, Ministry of Culture, Government of India). The protocol was approved by Institutional Animal Ethics Committee, Jamia Hamdard, New Delhi (approval no. 822) and the ARVO guidelines for animal usage were followed. Utmost
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 139
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
care was taken to ensure that animals were treated in the most humane and ethically acceptable manner. 6.3.4.7.1. Ocular retention study by Gamma scientigraphy The precorneal retention of mucoadhesive NE system was assessed by γ- scintigraphy. The liquid radio labelling of CYA suspension, NE, CH-NE were done using
99m
Tc as per the
protocol developed by INMAS, New Delhi. Labelling efficiency was determined using instantaneous thin layer chromatography (ITLC) and was found to be greater than 98% for more than 6 h in all the cases. Corneal retention of
99m
Tc labelled mucoadhesive
nanoemulsion was compared with 99mTc labelled NE and CYA suspension. A total of 20 μL of the labelled formulations were instilled into the cul-de-sac of the left eye of the rabbit, and the eye was manually blinked three times to distribute the formulation over the cornea. The right eye of each rabbit served as a negative control. Gamma camera (Millenium VG, Milwaukee, Wisconsin), autotuned to detect the 140 KeV radiation of Tc-99m, was used for scintigraphy study. Rabbits were anesthetized to made ease of the study by using ketamine HCl injection given intramuscularly in a dose of 15 mg/ kg body weight. The rabbits were positioned 5 cm in front of the probe, and 50 μL of the radiolabeled formulation was instilled onto the left corneal surface of each rabbit. Recording was started 5 seconds after instillation and continued for 30 minutes using 128 × 128 pixel matrix. Sixty individual frames (60 × 30 seconds) were captured by dynamic imaging process. Region of interest (ROI) was selected on one frame of the image, and time activity curve was plotted to calculate the rate of drainage from the eye. Two minute static images were also taken at 0.5, 1, 2, 4 and 6 h postinstillation. All the images were recorded on a computer system assisted with the software Entegra Version-2. 6.3.4.7.2. Biodistribution study of CYA in cornea, conjunctiva, aqueous humor and blood
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 140
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Three groups, each having seven New Zealand Albino rabbits (2.25±0.25 kg), were used for the ocular study. Each group received, in both the eyes, a single topical instillation (50 µL) of nanoemulsions (B1), CH coated mucoadhesive nanoemulsions (CH-B1) and suspension in water (CYA-sus), containing dose equivalent to 0.5% w/v of CYA. At different times postinstillation (0.5, 6, 12 and 24 h), the aqueous humour was withdrawn from the anterior chamber with the aid of a 25-gauge needle fitted to an insulin syringe. Prior to sacrifice of rabbit, blood samples were collected at the above mentioned times from the marginal ear vein in tubes containing heparin and immediately centrifuged at 37°C, 4500 rpm for 4 min and the plasma fraction was then quickly separated. In addition, the eyes were proptosed and rinsed with normal saline. Cornea and conjunctiva were subsequently dissected in situ. Each tissue was rinsed with normal saline, blotted dry in order to remove any adhering drug and transferred to pre-weighed counting vials. The vials were re-weighed and the weight of the tissues was calculated. All the biological samples were then analyzed by UPLC/Q-TOFMS/MS. 6.3.4.8. Statistical analysis Data of in vivo analysis was expressed as mean of experimental value ± S.D. The data was compared for statistical significance by the one-way analysis of variance (ANOVA) followed by Tukey–Kramer multiple comparisons test using GraphPad Instat software (GraphPad Software Inc., CA, USA). 6.4. Result and Discussion 6.4.1. Determination of solubility of cyclosporine A in oils, surfactants and cosurfactants Being a moderately lipophilic drug, it was very important to find out an appropriate solvent to dissolve cyclosporin A, because only the dissolved state of drug in moderately lipophilic carrier facilitates the drug permeation (Akhter et al., 2008). In order to screen appropriate
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 141
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
solvent/s for the preparation of NE, the solubility of cyclosporin A in various oils, surfactants and co-surfactants was measured. After performing solubility study in different oils, it was found that cyclosporin A exhibited maximum solubility in the oleic acid (21.79±0.93 mg/mL) [table 6.1; figure 6.1]. Table 6.1: Solubility of cyclosporin A in different oils S.No
Oils
Solubility (mg/ml±S.D)
1
Oleic acid
21.79±0.93
2
Ispropyl myristate (IPM)
3.42±0.14
3
Olive oil
11.21±0.27
4
Triacetin
0.47±0.03
5
Castor oil
09.11±0.81
6
Labrafac
2.80±0.04
7
Soyabean oil
1.23±0.11
8
Safsol
3.25±0.06
Figure 6.1: Solubility of cyclosporin A in different selected oils.
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 142
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Therefore oleic acid was chosen as the oil phase. The other advantage with the use of oleic acid that it has also been reported it is a powerful penetration enhancer for lipophilic barriers (Rhee et al., 2001), as it increases the fluidity of the intercellular lipid barriers by forming separate domains which interfere with the continuity of the multi-lamellar corneal epithelial and induce highly permeable pathways (Akhter et al., 2011) and such mechanism is supported by the work carried out on transdermal delivery by Puranjoti et al (Puranjoti et al., 2002). Based on preliminary solubility studies, the surfactants; polysorbate 20 (Tween 20) (1.16 ±0.19 mg/mL), polysorbate 80 (Tween 80) (1.13 ±0.15 mg/mL), polyethoxylated castor oil (Cremophore EL) (1.50±0.41mg/mL) and caprylocaproyl macrogol- 8-glyceride (Labrasol) (2.50±0.70 mg/mL) and co-surfactants; Transcutol P (Transcutol P) (2.73±0.41 mg/mL), PEG 200 (2.15±0.45 mg/mL), PEG 400 (2.68±0.39 mg/mL) and propylene glycol (1.30 ±0.40 mg/mL) showing comparable solubility of drug, were chosen for further optimization of NE formulations (table 6.2; figure 6.2). Table 6.2: Solubility of cyclosporin A in surfactants and co-surfactants S. No.
Surfactants
Solubility (mg/ml)
1
Tween 20
1.16 ±0.19
2
Tween 80
1.13 ±0.15
3
Cremophore EL
1.50±0.41
4
Labrasol
2.50±0.70
5
Span 20
0.62±0.13
7
Lauroglycol 90
0.50±0.10
8
Labrafil M
0.84±0.14
Co-surfactants 9
Transcutol P
2.73±0.41
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 143
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation 10
PEG 200
2.15±0.45
11
PEG 400
2.68±0.39
12
Propylene glycol
1.30 ±0.40
Figure 6.2: Solubility profile of cyclosporin A in different selected surfactants and cosurfactants. 6.4.2. Screening & optimization of surfactant and co- surfactants The screening of surfactant and cosurfactant on the basis of solubility is difficult because there is no significant difference in solubility of drug among these surfactant and cosurfactant. So, in this work, we carried out the selection of surfactant and cosurfactant was based on formation of larger NE region in the pseudo ternary phase diagram. Constructed pseudo-ternary phase diagrams are self explanatory about the presence of NE region which assists easy selection of ingredients proportions for preparation of stable formulation (Akhter et al., 2008; Eccleston., 1992). Large NE region would also facilitate the selection of formulation with low surfactant and cosurfactant concentration, desirable for preparing non irritating formulations particularly to the eyes. For optimization of surfactant, initially cosurfactant Transcutol P was kept constant, different surfactant Tween 20, Tween 80, Cremophore EL and Labrasol in 1:1 ratio with
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 144
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
cosurfactant (Transcutol P) was used. For each phase diagram, oil and specific Smix were mixed well in different ratios. Sixteen different combinations of oil and Smix (1:9, 1:8, 1:7, 1:6, 1:5 1:4, 1:3.5, 1:3, 3:7, 1:2, 4:6, 5:5, 6:4, 7:3, 8:2 and 9:1) were made for phase diagram construction. Each combination was titrated with water and the resultant physical state of NE was marked on a pseudo ternary phase diagram with one axis representing the water, one representing oil and the third representing a Smix. The combinations is presented in the table 6.3, the titrating ratios of oil, Smix and aqueous phase are given in table 6.4-6.8 and pseudo ternary phase diagram for the corresponding titration are presented in figure 6.3-6.6.
Table 6.3: Oil, surfactants cosurfactant and their combination ratios used for the optimization of surfactant Oil Phase
Cosurfactant Surfactant
Smix (Cosurfactant: Surfactant)
Oil: Smix Ratio
Tween20 Cremophore EL
Oleic Acid
Transcutol P
1:1 Tween80
1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3.5, 1:3, 3:7, 1:2, 1:1, 2:3, 6:4, 7:3, 8:2 and 9:1
Labrasol
Inference
Large nanoemulsion area Large nanoemulsion area Smaller nanoemulsion area Poor nanoemulsion area
Table 6.4: Nanoemulsion points for the mixture containing Smix ratio 1:1 Oil phase- oleic acid Smix- surfactant: cosurfactant Surfactant: tween20 Cosurfactant: Transcutol P
S. No.
1.
% Oil
% Smix
(v/v)
(v/v)
6.45
58.06
Ratio (oil: Smix)
%Water (v/v)
1:9
35.48
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 145
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
2.
6.06
54.55
1:9
39.39
3.
5.56
50.00
2:8
44.44
4.
5.00
45
2:8
50
5.
4.55
40.19
2:7
54.55
6.
4.20
40.00
1:5
54.34
7.
4.00
36.00
1:5
60.00
8.
3.51
31.58
1:5
64.00
9.
28.17
56.34
1:5
15.49
10.
20.69
48.28
1:5
31.03
11.
22.22
51.85
1:5
25.93
12.
24.00
56
1:5
20.00
13.
10.00
50.00
1:5
40.00
14.
29.39
62.17
1:3
10.43
15.
26.69
59.07
1:3
14.23
16.
20
60
1:3
20
17.
21.28
63.83
1:3
14.89
18.
15.50
54.26
1:3.5
30.23
19.
16.67
58.33
1:3.5
25
20.
17.70
61.95
1:3.5
20.35
21.
18.87
66.04
1:3.5
15.09
22.
12.90
51.61
1:4
35.48
23.
13.79
55.17
1:4
31.03
24.
14.81
59.26
1:4
25.93
25.
16
64
1:4
20
26.
16.67
66.67
1:4
16.67
27.
10
50
1:5
40
28.
10.81
54.05
1:5
35.14
29.
11.56
57.80
1:5
30.64
30.
12.50
62.50
1:5
25
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 146
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
31.
13.33
66.67
1:5
20
32.
7.84
47.06
1:6
45.10
33.
8.58
51.50
1:6
39.91
34.
9.26
55.56
1:6
35.19
35.
10
60
1:6
30
36.
10.70
64.17
1:6
25.13
37.
11.43
68.57
1:6
20
38.
4.55
40.91
1:5
45.45
39.
11.56
57.80
1:5
30.64
40.
13.79
55.17
1:6
31.03
41.
11.56
57.80
16
30.64
42.
14.00
56.43
1:6
30.07
43.
8.13
56.91
1:6
34.96
44.
8.70
60.87
1:6
30.43
45.
9.35
65.42
1:6
25.23
46.
10.00
50.00
1:6
40.00
47.
8.82
60.87
1:7
30.45
48.
9.09
45.00
1:7
45.45
49.
6.12
48.93
1:7
44.95
50.
6.67
53.76
1:7
40.02
51.
7.22
57.76
1:7
35.02
52.
5.56
50.00
1:7
44.44
53.
9.09
81.82
1:8
9.09
6.
4.20
40.00
1:8
54.34
55.
6
45
1:8
49.00
56.
5
35
1:8
60.00
57.
6.90
62.07
1:8
31.03
58.
6.45
58.06
1:8
35.48
59.
6.06
54.55
1:8
39.39
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 147
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
60.
5.56
50
1:8
44.44
61.
5
45
1:8
50
Figure 6.3: Pseudoternary phase diagram showing o/w nanoemulsion region for S/ CoS ratio 1:1(Tween20: Transcutol P).
Table 6.5: Nanoemulsion points for the mixture containing Surfactant/ Co-Surfactant ratio 1:1
Oil phase: Oleic acid Surfactant: Cremophore EL Cosurfactant: Transcutol P
S. No.
% Oil
% Smix
Ratio (oil: Smix)
%Water
(v/v)
(v/v)
1.
6.06
54.55
1:9
39.39
2.
5.56
50.00
1:9
44.44
3.
11.11
44.44
1:9
44.44
4.
10.10
40.40
1:9
50.00
5.
9.09
36.36
1:9
54.55
6.
8.00
32.00
1:9
60.00
7.
7.49
37.45
1:9
55.06
(v/v)
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 148
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
8.
6.67
33.33
2:8
60.00
9.
5.80
28.99
2:8
65.22
10.
5.00
25.00
2:8
70.00
11.
10.00
60.00
1:5
30.00
12.
9.26
55.56
1:5
35.19
13.
8.58
51.50
1:5
39.91
14.
7.84
47.06
1:5
45.10
15.
8.70
60.87
1:6
30.00
16.
8.13
56.91
1:6
34.96
17.
7.49
52.43
1:6
40.07
18.
6.78
47.46
1:6
45.76
19.
7.75
62.02
1:6
30.23
20.
7.22
57.76
1:6
35.02
21.
6.67
53.33
1:6
40.00
22.
6.12
48.34
1:6
44.45
23.
5.56
44.44
1:6
50.00
24.
9.26
55.56
1:7
35.19
25.
10
60
1:7
30
26.
10.70
64.17
1:7
25.13
27.
6.25
43.75
1:7
50
28.
6.78
47.46
1:7
45.76
29.
7.49
52.43
1:7
40.07
30.
8.13
56.91
1:7
34.96
31.
8.70
60.87
1:7
30.43
32.
9.35
65.42
1:7
25.23
33.
10
70
1:7
20
34.
5
40
1:7
55
35.
5.56
44.44
1:7
50
36.
6.12
48.93
1:7
44.95
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 149
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
37.
6.67
53.33
1:7
40
38.
7.22
57.76
1:8
35.02
39.
7.75
62.02
1:8
30.23
40.
8.33
66.67
1:8
25
41.
7.41
66.67
1:8
25.93
42.
6.90
62.07
1:8
31.03
43.
6.45
58.06
1:8
35.48
44.
6.06
54.55
1:8
39.39
45.
5.56
50
1:8
44.44
46.
5
45
1:8
50
47.
4.55
40.91
1:8
54.55
48.
4
36
1:8
60
Figure 6.4: Pseudoternary phase diagram showing o/w nanoemulsion region for surfactant/ cosurfactant ratio 1:1. (Cremophore EL: Transcutol P).
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 150
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Table 6.6: Nanoemulsion points for the mixture containing S/ CoS ratio 1:1 Oil phase: Oleic acid Surfactant: Tween 80 Cosurfactant: Transcutol P
S. No.
% Oil
% Smix
Ratio (oil: Smix)
%Water
(v/v)
(v/v)
1.
20.69
48.28
1:9
31.03
2.
17.39
52.17
1:9
30.43
3.
15.50
54.26
1:9
30.23
4.
12.90
51.61
1:9
35.48
5.
13.79
55.17
1:4
31.03
6.
10
50
1:4
40
7.
10.81
54.05
1:3.5
35.14
8.
15.56
57.80
1:3.5
33.64
9.
7.84
47.06
1:5
45.10
10.
8.58
51.50
1:5
39.91
11.
9.26
55.56
1:6
35.19
12.
10
60
1:6
30
13.
6.25
43.75
1:7
50
14.
6.78
47.46
1:7
45.76
15.
7.49
52.43
1:7
40.07
16.
8.13
56.91
1:8
34.96
17.
8.70
60.87
1:8
30.43
18.
5
40
1:8
55
(v/v)
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 151
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Figure 6.5: Pseudoternary phase diagram showing o/w nanoemulsion region for surfactant/ cosurfactant ratio 1:1. (Tween 80: Transcutol P) Table 6.7: Nanoemulsion points for the mixture containing S/ CoS ratio 1:1. Oil phase: Oleic acid Surfactant: Labrasol Cosurfactant: Transcutol P S. No.
% Oil
% Smix
Ratio (oil: Smix)
%Water
(v/v)
(v/v)
1
10
50
1:9
40
2
7.84
47.06
1:9
45.10
3
8.58
51.50
1:4
39.91
4
6.25
43.75
1:5
50
5
6.78
47.46
1:6
45.76
6
7.49
52.43
1:7
40.07
7
5
40
1:7
55
8
5.56
44.44
1:7
50
9
5.56
50
1:8
44.44
10
5
45
1:8
50
11
4.55
40.91
1:9
54.55
(v/v)
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 152
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Figure 6.6: Pseudoternary phase diagram showing o/w nanoemulsion region for surfactant/ cosurfactant ratio 1:1. (Labrasol: Transcutol P). After studying the results, maximum nanoemulsion areas were obtained with surfactant tween 20 and cremophore EL, therefore these surfactants were selected for further optimization of cosurfactant. Titrations were performed by using different cosurfactants (Transcutol P, PEG 200, PEG 400, propylene glycol) with the selected surfactants. The ratio of surfactant to cosurfactant (Smix ratio) was kept constant (1:1) while oil to Smix ratio was kept at 1:9 since higher concentration of Smix is favorable for maximum NE formation (Tenjarla., 1999; Shafiq et al., 2006). For the further titration, the combination of oil, Smix and water is presented in table 6.8.
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 153
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Table 6.8: The titrating combination of oil, Smix ratio and number of new points obtained
Oil phase
Surfactant
Cosurfactant
Smix (Cosurfactant: Surfactant)
Oil :Smix ratio
Transcutol
2
PEG 400
2
Transcutol
1:1
P Cremophore EL
points
PEG 200
PG
Oleic acid
nanoemulsion
4
P Tween 20
No. of
1:9
0 3
PEG 200
1
PEG 400
1
PG
0
After studying the result, it was found that maximum nanoemulsion region or points were obtained with Transcutol P and hence Transcutol P was chosen as cosurfactant for nanoemulsion formulation. Finally, this is inference here that Tween 20 and Cremophore EL showed maximum formation of NE with Transcutol P as cosurfactant. So, for the preparation of nanoemulsion formulation oleic acid was selected as oil, Tween 20 and Cremophore EL as surfactants (to validate the effect of different Smix combination on phase behavior) and Transcutol P as cosurfactant. For each phase diagram, Smix ratios 1:0, 1:1, 1:2, 2:1, 3:1, 1:3, 4:1, 1:4 was prepared. Oil and specific Smix were mixed well in different ratios. Sixteen different combinations of oil and Smix (1:9, 1:8, 1:7, 1:6, 1:5 1:4, 1:3.5, 1:3, 3:7, 1:2, 4:6, 5:5, 6:4, 7:3, 8:2 and 9:1) were made for phase diagram construction. For each Smix ratio separate phase diagram was constructed. Physical appearance of all NE formulations showed no distinct conversion boundaries from w/o to o/w at all Smix ratios. The rest of the region on the phase diagram represents the DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 154
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
turbid and conventional emulsions based on visual observation. Significant difference was seen in ternary phase diagrams of NE constructed with different Smix ratio (Table 6.4-6.5 and 6.9-6.19) and (Fig 6.3-6.4 and 6.7-6.17). Table 6.9: Nanoemulsion points for the mixture containing S/ CoS ratio 1:0 Oil Phase: Oleic acid. Surfactant: Tween 20 Cosurfactant: Nil
S. No.
% Oil
% Smix
Ratio (oil: Smix)
% Water
(v/v)
(v/v)
1.
40
40
1:9
20
2.
41.67
41.67
1:9
16.67
3.
45.45
45.45
1:4
15.09
4.
32
48
1:4
20
5.
11.56
57.80
1:4
30.64
6.
36.36
54.55
1:4
9.09
7.
25
50
1:4
25
8.
26.67
43.33
1:5
30
9.
13.17
56.34
1:5
41.49
10.
20.30
40.61
1:5
40.09
11.
22.22
51.85
1:5
25.93
12.
24
56
1:5
20
13.
11.56
57.80
1:6
30.64
14.
10.00
60.00
1:6
30.00
15.
8.70
60.87
1:6
30.43
16.
8.13
56.91
1:6
34.96
17.
22.22
66.67
1:6
11.11
18.
7.49
52.43
1:6
40.07
19.
6.25
43.75
1:6
50.00
(v/v)
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 155
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
20.
5.62
39.33
1:6
55.06
21.
5.00
35.00
1:6
60.00
22.
8.70
60.87
1:7
30.43
23.
10.56
57.80
1:7
31.64
24.
11.17
58.34
1:7
41.49
25.
18.18
52.73
1:7
32.09
26.
13.33
66.67
1:7
20.00
27.
14.08
70.42
1:7
15.49
28.
3.13
21.88
1:7
10.45
29.
2.50
17.50
1:7
80
30.
1.87
13.12
1:7
85.00
31.
1.25
8.75
1:7
90.00
32.
0.62
4.36
1:7
95.03
33.
10
70
1:8
30.00
34.
10.53
73.68
1:8
15.79
35.
7.75
62.02
1:8
30.23
36.
7.32
57.76
1:8
35.02
37.
6.67
53.33
1:8
40.00
38.
6.12
48.93
1:8
44.95
39.
5.56
44.44
1:8
50.00
40.
5.00
40.00
1:8
55.00
41.
3.88
31.07
1:8
65.05
42.
3.33
26.67
1:8
70.00
43.
2.78
22.22
1:8
75.00
44.
2.22
17.78
1:8
80.00
45.
1.67
13.33
1:8
85.00
46.
1.11
6.89
1:8
90.00
47.
0.56
4.44
1:8
95.00
48.
3.88
31.07
1:8
65.05
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 156
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
49.
5.00
40.00
1:8
55.00
50.
5.56
44.44
1:8
50.00
51.
6.06
54.55
1:8
39.39
Figure 6.7: Pseudoternary phase diagram showing o/w nanoemulsion region for surfactant/ cosurfactant ratio 1:0(Tween 20/ Transcutol P).
Table 6.10: Nanoemulsion points for the mixture containing S/ CoS ratio 2:1 Oil phase: Oleic acid. Surfactant: Tween 20 Cosurfactant: Transcutol P
S. No.
% Oil
% Smix
(v/v)
(v/v)
Ratio(oil: Smix)
% Water (v/v)
1.
11.56
57.80
1:9
30.64
2.
7.84
47.06
1:9
45.10
3.
10.00
60.00
1:9
30.00
4.
9.26
55.56
1:9
35.19
5.
54.55
36.36
1:4
9.09
6.
37.04
37.04
1:4
25.93
7.
40
40
1:4
20
8.
41.67
41.67
1:4
16.67
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 157
DES Chapter 6 9.
Cyclosporine A Nanoemulsion Formulation 45.45
45.45
1:2.3
9.09
10.
29.63
44.44
1:2.3
25.93
11.
23.26
46.51
1:2.3
30.23
12.
33.33
50
2:3
16.67
13.
20.69
48.28
1:3
31.03
14.
23.26
46.51
1:3
30.23
15.
25
50
1:3
25
16.
20.69
48.28
2:7
31.03
17.
11.56
57.80
2:7
30.64
18.
10.00
60.00
2:7
30.00
19.
20.69
48.28
2:7
31.03
20.
9.26
55.56
2:7
35.19
21.
24
56
1:5
20
22.
6.78
47.46
1:5
45.76
23.
6.25
43.75
1:5
50.00
24.
9.26
55.56
1:5
35.19
25.
10
50
1:5
40
26.
12.50
62.50
1:5
25
27.
13.33
66.67
1:5
20
28.
22.22
66.67
1:6
11.11
29.
14.39
50.36
1:6
35.25
30.
15.50
54.26
1:6
30.23
31.
16.67
58.33
1:6
25
32.
17.70
61.95
1:6
20.35
33.
18.87
66.04
1:6
15.09
34.
5.00
40.00
1:6
55.00
35.
12.90
51.61
1:6
35.48
36.
13.79
55.17
1:6
31.03
37.
6.67
53.33
1:6
40.00
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 158
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
38.
7.22
57.76
1:6
35.02
39.
6.12
48.93
1:6
44.95
40.
6.25
43.75
1:7
50
41.
6.78
47.46
1:7
45.76
42.
7.49
52.43
1:7
40.07
43.
8.13
56.91
1:7
34.96
44.
8.70
60.87
1:7
30.43
45.
9.35
65.42
1:7
25.23
46.
10
70
1:7
20
47.
10.53
73.68
1:7
15.79
48.
11.24
78.65
1:7
10.11
49.
8.58
51.50
1:7
39.91
50.
9.26
55.56
1:7
35.19
51.
10
60
1:7
30
52
10.70
64.17
1:6
25.13
53
11.43
68.57
1:6
20
54.
12.12
72.73
1:6
15.15
55.
12.82
76.92
1:6
10.26
56.
6.25
43.75
1:7
50
57.
6.78
47.46
1:7
45.76
58.
7.49
52.43
1:7
40.07
59.
8.13
56.91
1:7
34.96
60.
8.70
60.87
1:7
30.43
61.
9.35
65.42
1:7
25.23
62.
10
70
1:7
20
63.
10.53
73.68
1:7
15.79
64.
11.24
78.65
1:7
10.11
65.
0.56
4.44
1:7
95
66.
5
40
1:8
55
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 159
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
67.
5.56
44.44
1:8
50
68.
6.12
48.93
1:8
44.95
69.
6.67
53.33
1:8
40
70.
7.22
57.76
1:8
35.02
71.
7.75
62.02
1:8
30.23
72.
8.33
66.67
1:8
25
73.
8.89
71.11
1:8
20
74.
9.43
75.47
1:8
15.09
75.
10
50
1:8
40
76.
5.56
44.44
1:8
50
77.
6.67
53.00
1:8
40.00
s78.
8
42
1:8
50
79.
7.41
66.67
1:8
25.93
80.
6.90
62.07
1:8
31.03
81.
6.45
58.06
1:8
35.48
82.
5.56
50
1:8
44.44
83.
5
45
1:8
50
84.
3.51
31.58
1:8
64.91
85.
2.99
26.87
1:8
70.15
86.
2.5
22.5
1:8
75
87.
2
18
1:8
80
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 160
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Figure 6.8: Pseudoternary phase diagram showing o/w nanoemulsion region for surfactant/ cosurfactant ratio 2:1(Tween20/ Transcutol P).
Table 6.11: Nanoemulsion points for the mixture containing S/ CoS ratio 1:2 Oil phase: Oleic acid. Surfactant: Tween 20 Cosurfactant: Transcutol P
S. No.
% Oil
% Smix
Ratio (oil: S mix)
% Water
(v/v)
(v/v)
1.
0.48
4.29
1:9
95.24
2.
6.90
62.07
1:9
31.03
3.
8
72
1:9
20.00
4.
9.09
81.82
1:9
9.09
5.
8.5
76.5
1:9
15
6.
5
45
1:9
50
7.
4.5
40.5
1:9
55
8.
6
54
1:9
40
9.
7
63
1:9
30
10.
17.04
37.04
1:4
45.93
11.
10.04
25.04
1:4
65.93
(v/v)
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 161
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
12.
20
10
1:3.5
70
13.
18.18
72.73
1:4
9.09
14
10
40
1:4
50
15
15
60
1:4
25
16
17
15
1:4
68
17
19.25
3.75
1:4
77
18.
14.08
15.49
1:5
70.42
19.
14.93
10.45
1:5
74.63
20.
10
30
1:6
60
21.
12.12
15.15
1:6
72.73
22.
12.82
10.26
1:6
76.92
23.
10.53
15.79
1:7
73.68
24.
11.24
10.11
1:7
78.65
25.
8.89
20
1:8
71.11
26.
9.43
15.09
1:8
75.47
27.
10
10.00
1:8
80
28
7.75
30.25
1:8
62
29.
0.48
95.24
1:8
4.29
30.
6.90
31.03
1:8
62.07
31.
8
20.00
1:8
72
32.
9.09
9.09
1:8
81.82
33
8.5
15
1:8
76.5
34
5
50
1:8
45
35
4.5
55
1:8
40.5
36
6
40
1:8
54
37
7
30
1:8
63
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 162
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Figure 6.9: Pseudoternary phase diagram showing o/w nanoemulsion region for surfactant/ cosurfactant ratio 1:2(Tween20/ Transcutol P).
Table 6.12: Nanoemulsion points for the mixture containing S/ CoS ratio 3:1 Oil phase: Oleic acid. Surfactant: Tween 20 Cosurfactant: Transcutol P
S. No.
% Oil
% Smix
Ratio (oil: Smix)
%Water
(v/v)
(v/v)
1.
48
32
1:0.6
20
2.
50
33.33
1:0.6
16.67
3.
40
40
1:1
20
4.
41.67
41.67
1:1
16.67
5.
45.45
45.45
1:1
9.09
6.
32
48
1:1.5
20
7.
33.33
50
1:1.5
16.67
8.
36.36
54.55
1:1.5
9.09
9.
25
50
1:2
25
10.
26.67
53.33
1:2
20
11.
28.17
56.34
1:2
15.49
(v/v)
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 163
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
12.
30.30
60.61
1:2
9.09
13.
20.69
48.28
1:2.3
31.03
14.
22.22
51.85
1:2.3
25.93
15.
24
56
1:2.3
20
16.
25
58.33
1:2.3
16.67
17.
27.27
63.64
1:2.3
9.09
18.
17.39
52.17
1:3
30.43
19.
18.69
56.07
1:3
25.23
20.
20
60
1:3
20
21.
21.28
63.83
1:3
14.89
22.
22.22
66.67
1:3
11.11
23.
15.50
54.26
1:3.5
30.23
24.
16.67
58.33
1:3.5
25
25.
17.70
61.95
1:3.5
20.35
26.
18.87
66.04
1:3.5
15.09
27.
20
70
1:3.5
10
28.
12.90
51.61
1:4
35.48
29.
13.79
55.17
1:4
31.03
30.
14.81
59.26
1:4
25.93
31.
16
64
1:4
20
32.
16.67
66.67
1:4
16.67
33.
18.18
72.73
1:4
9.09
34.
10
50
1:5
40
35.
10.81
54.05
1:5
35.14
36.
11.56
57.80
1:5
30.64
37.
12.50
62.50
1:5
25
38.
13.33
66.67
1:5
20
39.
14.08
70.42
1:5
15.49
40.
14.93
74.63
1:5
10.45
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 164
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
41.
7.84
47.06
1:6
45.10
42.
8.58
51.50
1:6
39.91
43.
9.26
55.56
1:6
35.19
44.
10
60
1:6
30
45.
10.70
64.17
1:6
25.13
46.
11.43
68.57
1:6
20
47.
12.12
72.73
1:6
15.15
48.
12.82
76.92
1:6
10.26
49.
6.25
43.75
1:7
50
50.
6.78
47.46
1:7
45.76
51.
7.49
52.43
1:7
40.07
52.
8.13
56.91
1:7
34.96
53.
8.70
60.87
1:7
30.43
54.
9.35
65.42
1:7
25.23
55.
10
70
1:7
20
56.
10.53
73.68
1:7
15.79
57.
11.24
78.65
1:7
10.11
58.
5
40
1:8
55
59.
5.56
44.44
1:8
50
60.
6.12
48.93
1:8
44.95
61.
6.67
53.33
1:8
40
62.
7.22
57.76
1:8
35.02
63.
7.75
62.02
1:8
30.23
64.
8.33
66.67
1:8
25
65.
8.89
71.11
1:8
20
66.
9.43
75.47
1:8
15.09
67.
10
80
1:8
10
68.
9.09
81.82
1:9
9.09
69.
8.33
75
1:9
16.67
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 165
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
70.
8
72
1:9
20
71.
7.41
66.67
1:9
25.93
72.
6.90
62.07
1:9
31.03
73.
6.45
58.06
1:9
35.48
74.
6.06
54.55
1:9
39.39
75.
5.56
50
1:9
44.44
76.
5
45
1:9
50
77.
4.55
40.91
1:9
54.55
78.
4
36
1:9
60
79.
3.51
31.58
1:9
64.91
80.
2.99
26.87
1:9
70.15
81.
2.5
22.5
1:9
75
82.
2
18
1:9
80
83.
1.54
13.85
1:9
84.62
84.
1
9
1:9
90
85.
0.48
4.29
1:9
95.24
Figure 6.10: Pseudoternary phase diagram showing o/w nanoemulsion region for surfactant/ cosurfactant ratio 3:1 (Tween20/ Transcutol P).
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 166
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Table 6.13: Nanoemulsion points for the mixture containing S/ CoS ratio 1:3. Oil Phase: Oleic acid Surfactant: Tween 20 Cosurfactant: Transcutol P
S. No.
% Oil
% Smix
(v/v)
(v/v)
Ratio (oil: S mix)
% Water (v/v)
1.
36.36
54.55
1:1.5
9.09
2.
48
32
1:0.6
20
3.
63.64
27.27
1:0.42
9.09
4.
28.17
56.34
1:2
15.49
5.
30.30
60.61
1:2
9.09
6.
24
56
1:2.3
20
7.
25
58.33
1:2.3
16.67
8.
27.27
63.64
1:2.3
9.09
9.
21.28
63.83
1:3
14.89
10.
22
66.67
1:3
11.11
11.
18.87
66.04
1:3.5
15.09
12.
20
70
1:3.5
10
13.
18.18
72.73
1:4
9.09
14.
14.08
70.42
1:5
15.49
15.
14.93
74.63
1:5
10.45
16.
10
60
1:6
30
17.
12.12
72.73
1:6
15.15
18.
12.82
76.92
1:6
10.26
19.
10.53
73.68
1:7
15.79
20.
11.24
78.65
1:7
10.11
21.
8.89
71.11
1:8
20
22.
9.43
75.47
1:8
15.09
23.
10
80
1:8
10.00
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 167
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
24.
0.48
4.29
1:9
95.24
25.
6.90
62.07
1:9
31.03
26.
8
72
1:9
20.00
27.
9.09
81.82
1:9
9.09
Figure 6.11: Pseudoternary phase diagram showing o/w nanoemulsion region for surfactant/ cosurfactant ratio 1:3 (Tween20/ Transcutol P).
Table 6.14: Nanoemulsion points for the mixture containing S/ CoS ratio 4:1 Oil phase: Oleic acid. Surfactant: Tween 20 Cosurfactant: Transcutol P
S. No.
% Oil
% Smix
Ratio (oil: Smix)
% Water
(v/v)
(v/v)
1.
40
40
1:1
20
2.
41.67
41.67
1:1
16.67
3.
45.45
45.45
1:1
9.09
4.
32
48
1:1.5
20
5.
33.33
50
1:1.5
16.67
6.
36.36
54.55
1:1.5
9.09
7.
25
50
1:2
25
(v/v)
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 168
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation 8.
26.67
53.33
1:2
20
9.
28.17
56.34
1:2
15.49
10.
30.30
60.61
1:2
9.09
11.
22.22
51.85
1:2.3
25.93
12.
24
56
1:2.3
20
13.
25
58.33
1:2.3
16.67
14.
27.27
63.64
1:2.3
9.09
15.
20
60
1:3
20
16.
21.28
63.83
1:3
14.89
17.
22.22
66.67
1:3
11.11
18.
16.67
58.33
1:3.5
25
19.
17.70
61.95
1:3.5
20.35
20.
18.87
66.04
1:3.5
15.09
21.
20
70
1:3.5
10
22.
14.81
59.26
1:4
25.93
23.
16
64
1:4
20
24.
16.67
66.67
1:4
16.67
25.
18.18
72.73
1:4
9.09
26.
13.33
66.67
1:5
20
27.
14.08
70.42
1:5
15.49
28.
14.93
74.63
1:5
10.45
29.
11.43
6.57
1:6
20
30.
12.12
72.73
1:6
15.15
31.
12.82
76.92
1:6
10.26
32.
9.35
65.42
1:7
25.23
33.
10
70
1:7
20
34.
10.53
73.68
1:7
15.79
35.
11.24
78.65
1:7
10.11
36.
8.33
66.67
1:8
25
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 169
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
37.
8.89
71.11
1:8
20
38.
9.43
75.47
1:8
15.09
39.
10
80
1:8
10
40.
9.09
81.82
1:9
9.09
41.
8.33
75
1:9
16.67
42.
8
72
1:9
20
43.
7.41
66.67
1:9
25.9
44.
6.90
62.07
1:9
31.03
45.
9.09
81.82
1:9
9.09
46.
8.33
75
1:9
16.67
47.
8
72
1:9
20
48.
7.41
66.67
1:9
25.93
49.
6.90
62.07
1:9
31.03
50.
6.45
58.06
1:9
35.48
51.
6.06
54.55
1:9
39.39
Figure 6.12: Pseudoternary phase diagram showing o/w nanoemulsion region for surfactant/ cosurfactant ratio 4:1 (Tween20/ Transcutol P).
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 170
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Table 6.15: Nanoemulsion points for the mixture containing S/ CoS ratio 1:0 Oil Phase: Oleic acid Surfactant: Cremophore EL Cosurfactant: Nil
S. No.
% Oil
% Smix
(v/v)
(v/v)
Ratio (oil: S mix)
% Water (v/v)
1.
36.36
54.55
1:1.5
9.09
2.
48
32
1:0.6
20
3.
63.64
27.27
1:0.42
9.09
4.
28.17
56.34
1:2
15.49
5.
30.30
60.61
1:2
9.09
6.
24
56
1:2.3
20
7.
25
58.33
1:2.3
16.67
8.
27.27
63.64
1:2.3
9.09
9.
21.28
63.83
1:3
14.89
10.
22
66.67
1:3
11.11
11.
18.87
66.04
1:3.5
15.09
12.
20
70
1:3.5
10
13.
18.18
72.73
1:4
9.09
14.
14.08
70.42
1:5
15.49
15.
14.93
74.63
1:5
10.45
16.
10
60
1:6
30
17.
12.12
72.73
1:6
15.15
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 171
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Figure 6.13: Pseudoternary phase diagram showing o/w nanoemulsion region for surfactant/ cosurfactant ratio 1:0. (Cremophore EL/Transcutol P).
Table 6.16: Nanoemulsion points for the mixture containing S/ CoS ratio 1:2 Oil phase: Oleic acid. Surfactant: Cremophore EL Cosurfactant: Transcutol P
S. No.
% Oil
% Smix
(v/v)
(v/v)
Ratio (oil: Smix) % Water (v/v)
1.
40
40
1:1
20
2.
41.67
41.67
1:1
16.67
3.
45.45
45.45
1:1
9.09
4.
32
48
1:1.5
20
5.
33.33
50
1:1.5
16.67
6.
36.36
54.55
1:1.5
9.09
7.
25
50
1:2
25
8.
26.67
53.33
1:2
20
9.
28.17
56.34
1:2
15.49
10.
30.30
60.61
1:2
9.09
11.
22.22
51.85
1:2.3
25.93
12.
24
56
1:2.3
20
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 172
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
13.
25
58.33
1:2.3
16.67
14.
27.27
63.64
1:2.3
9.09
15.
20
60
1:3
20
16.
21.28
63.83
1:3
14.89
17.
22.22
66.67
1:3
11.11
18.
16.67
58.33
1:3.5
25
19.
17.70
61.95
1:3.5
20.35
20.
18.87
66.04
1:3.5
15.09
21.
20
70
1:3.5
10
22.
14.81
59.26
1:4
25.93
23.
16
64
1:4
20
24.
16.67
66.67
1:4
16.67
25.
18.18
72.73
1:4
9.09
26.
13.33
66.67
1:5
20
27.
14.08
70.42
1:5
15.49
28.
14.93
74.63
1:5
10.45
29.
11.43
6.57
1:6
20
30.
12.12
72.73
1:6
15.15
Figure 6.14: Pseudoternary phase diagram showing o/w nanoemulsion region for surfactant/ cosurfactant ratio 1:2. (Cremophore EL/Transcutol P). DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 173
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Table 6.17: Nanoemulsion points for the mixture containing S/ CoS ratio 2:1 Oil Phase: Oleic acid Surfactant: Cremophore EL Cosurfactant: Transcutol P
S. No.
% Oil
% Smix
(v/v)
(v/v)
Ratio (oil: S mix)
% Water (v/v)
1.
36.36
54.55
1:1.5
9.09
2.
48
32
1:0.6
20
3.
63.64
27.27
1:0.42
9.09
4.
28.17
56.34
1:2
15.49
5.
30.30
60.61
1:2
9.09
6.
24
56
1:2.3
20
7.
25
58.33
1:2.3
16.67
8.
27.27
63.64
1:2.3
9.09
9.
21.28
63.83
1:3
14.89
10.
22
66.67
1:3
11.11
11.
18.87
66.04
1:3.5
15.09
12.
20
70
1:3.5
10
13.
18.18
72.73
1:4
9.09
14.
14.08
70.42
1:5
15.49
15.
14.93
74.63
1:5
10.45
16.
10
60
1:6
30
17.
12.12
72.73
1:6
15.15
18.
12.82
76.92
1:6
10.26
19.
10.53
73.68
1:7
15.79
20.
11.24
78.65
1:7
10.11
21.
8.89
71.11
1:8
20
22.
9.43
75.47
1:8
15.09
23.
10
80
1:8
10.00
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 174
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
24.
0.48
4.29
1:9
95.24
25.
6.90
62.07
1:9
31.03
26.
8
72
1:9
20.00
27.
9.09
81.82
1:9
9.09
Figure 6.15: Pseudoternary phase diagram showing o/w nanoemulsion region for surfactant/ cosurfactant ratio 2:1. (Cremophore EL/Transcutol P).
Table 6.18: Nanoemulsion points for the mixture containing S/ CoS ratio 1:3 Oil Phase: Oleic acid Surfactant: Cremophore EL Cosurfactant: Transcutol P
S. No.
% Oil (v/v)
% Smix (v/v)
Ratio (oil: S mix) % Water(v/v)
1.
36.36
54.55
1:1.5
9.09
2.
48
32
1:0.6
20
3.
63.64
27.27
1:0.42
9.09
4.
28.17
56.34
1:2
15.49
5.
30.30
60.61
1:2
9.09
6.
24
56
1:2.3
20
7.
25
58.33
1:2.3
16.67
8.
27.27
63.64
1:2.3
9.09
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 175
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
9.
21.28
63.83
1:3
14.89
10.
22
66.67
1:3
11.11
11.
18.87
66.04
1:3.5
15.09
12.
20
70
1:3.5
10
13.
18.18
72.73
1:4
9.09
14.
14.08
70.42
1:5
15.49
15.
14.93
74.63
1:5
10.45
16.
10
60
1:6
30
17.
12.12
72.73
1:6
15.15
18.
12.82
76.92
1:6
10.26
19.
10.53
73.68
1:7
15.79
20.
11.24
78.65
1:7
10.11
21.
8.89
71.11
1:8
20
22.
9.43
75.47
1:8
15.09
23.
10
80
1:8
10.00
Figure 6.16: Pseudoternary phase diagram showing o/w nanoemulsion region for surfactant/ cosurfactant ratio 1:3. (Cremophore EL/Transcutol P).
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 176
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Table 6.19: Nanoemulsion points for the mixture containing S/ CoS ratio 3:1 Oil phase: Oleic acid. Surfactant: Cremophore EL Cosurfactant: Transcutol P
S. No.
% Oil
% Smix
Ratio (oil: Smix)
% Water
(v/v)
(v/v)
1.
40
40
1:1
20
2.
41.67
41.67
1:1
16.67
3.
45.45
45.45
1:1
9.09
4.
32
48
1:1.5
20
5.
33.33
50
1:1.5
16.67
6.
36.36
54.55
1:1.5
9.09
7.
25
50
1:2
25
8.
26.67
53.33
1:2
20
9.
28.17
56.34
1:2
15.49
10.
30.30
60.61
1:2
9.09
11.
22.22
51.85
1:2.3
25.93
12.
24
56
1:2.3
20
13.
25
58.33
1:2.3
16.67
14.
27.27
63.64
1:2.3
9.09
15.
20
60
1:3
20
16.
21.28
63.83
1:3
14.89
17.
22.22
66.67
1:3
11.11
18.
16.67
58.33
1:3.5
25
19.
17.70
61.95
1:3.5
20.35
20.
18.87
66.04
1:3.5
15.09
21.
20
70
1:3.5
10
22.
14.81
59.26
1:4
25.93
23.
16
64
1:4
20
(v/v)
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 177
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
24.
16.67
66.67
1:4
16.67
25.
18.18
72.73
1:4
9.09
26.
13.33
66.67
1:5
20
27.
14.08
70.42
1:5
15.49
28.
14.93
74.63
1:5
10.45
29.
11.43
6.57
1:6
20
30.
12.12
72.73
1:6
15.15
31.
12.82
76.92
1:6
10.26
32.
9.35
65.42
1:7
25.23
33.
10
70
1:7
20
34.
10.53
73.68
1:7
15.79
35.
11.24
78.65
1:7
10.11
36.
8.33
66.67
1:8
25
37.
8.89
71.11
1:8
20
38.
9.43
75.47
1:8
15.09
39.
10
80
1:8
10
40.
9.09
81.82
1:9
9.09
41.
8.33
75
1:9
16.67
42.
8
72
1:9
20
43.
7.41
66.67
1:9
25.9
44.
6.90
62.07
1:9
31.03
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 178
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Figure 6.17: Pseudoternary phase diagram showing o/w nanoemulsion region for surfactant/ cosurfactant ratio 3:1. (Cremophore EL/Transcutol P).
Physical appearance of all NE formulations with Tween 20 and Cremophore EL as surfactant showed no distinct conversion boundaries from w/o to o/w at all of their Smix ratios with Transcutol P as cosurfactant. The rest of the region on the phase diagram represents the turbid and conventional emulsions based on visual observation. Significant difference was seen in ternary phase diagrams of NE constructed with different Smix ratio. It was observed, when Tween 20 and Cremophore EL was used alone without Transcutol P (Smix ratio 1:0), very low amount of oleic acid could be solubilized at high concentration (>55% w/w) of polysorbate 20 (Table 6.9, Table 6.15 and Figure 6.7. Figure 6.13). This could be attributed to the fact that transient negative interfacial tension and fluid interfacial film is rarely achieved by the use of single surfactant, usually necessitating the addition of a cosurfactant (Lawrence et al., 2000, Akhter et al., 2008, Akhter et al., 2011).
At equal amounts of surfactants and Transcutol P (Smix ratio 1:1), the NE region in the phase diagram increased significantly (Figure. 6.4 and Figure 6.5) compared to that obtained at Smix ratio 1:0 (Figure 6.7 and Figure 6.13). The presence of Transcutol P (cosurfactant) decreases the bending stress of interface and makes the interfacial film sufficiently flexible to take up different curvatures required to form
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 179
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
NE over a wide range of compositions (Kawakami et al., 2002). However, when concentration of Transcutol P with respect to surfactants was increased (Smix ratio 1:2 and 1:3) the NE area was decreased (Figure 6.9, Figure 6.14 and Figure 6.11, Figure 6.16 respectively) compared to Smix ratio 1:1 (Figure. 6.4 and Figure 6.5). The decrease in the NE area is possibly due to presence of low concentration of surfactant which reduces the amount of micelles and consequently decreases the solubilisation capacity of NE (Yuan et al., 2008). Moreover, NEs formed at Smix ratio 1:3 were unstable and showed phase separation within 24 h. More particularly, as compared to the Tween 20, Cremophore EL as surfactant showed lesser phase area at all the studied Smix. With further increase in Transcutol P concentration (Smix ratio 1:4), not a single NE point was found in both the cases. In contrast to this, when concentration of Transcutol P with respect to polysorbate 20 and Cremophore EL was decreased (Smix ratio 2:1), the NE area was increased (Figure 6.8 and Figure 6.15) compared to their respective Smix ratio 1:1 (Figure. 6.4 and Figure 6.5). However, at further lower Transcutol P concentrations (Smix ratio 3:1 and 4:1), the NE area was decreased, it was because Transcutol P is a polar solvent with the tendency to highly incorporate into water, and the relatively lower Transcutol P content in the NE system decreases the hydrophilicity of the Smix, so the area of o/w NE was decreased. In brief, Nanoemulsion system at Smix ratio 2:1 formed large isotropic NE region than the systems at other Smix ratios with both the surfactants. NEs formation behaviour of Tween 20 is significantly larger than the Cremophore EL with Transcutol P as cosurfactant. Moreover, at Smix ratio 2:1 and 3:1 of Cremophore EL with Transcutol P produces larger number of NEs gel form with is not suitable for the topical solution delivery in eyes. Such phase behaviour is commonly seen with polyethylene glycol ethers of castor oil like Cremophore EL (Akhter et al., 2008; Akhter et al., 2011).
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 180
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
After extensively evaluating the phase behaviour of Tween 20 and Cremophore EL we concluded here that among the surfactant, Tween 20 is best for the development of nanoemulsion formulation with Transcutol P as the cosurfactant. So, for the further study, we selected nanoemulsion formulation from the different phase ratios of Tween 20 and Transcutol P. The selected components for the nanoemulsion formulation development have appropriate features considering for the topical ocular drug delivery. Oleic acid (oil phase) is a well known permeation enhancer, itself the integral part of corneal lipids and nontoxic and considered to be safe for ophthalmic drug delivery. Tween 20 being a nonionic surfactant and Transcutol P as cosurfactant are non irritant and effective corneal permeation enhancers (Li et al., 2008; Liu et al., 2006). 6.4.3. Selection of nanoemulsion formulations from different Smix ratios
Following criteria were chosen for the selection of formulations: •
The oil and Smix concentration should be such that it solubilises the single dose of the drug and give the final concentration of 3% w/v.
•
Formulations with Smix ratio 1:3 and 4:1 were not selected because of the presence of Nanoemulsion is very less in number and such formulation required very high surfactant concentration (>50%). Nanoemulsion from phase diagram of Smix ratio 4:1 showed high viscosity as well as high surfactant were required to develop the nanoemulsion system.
•
High concentration of surfactant which might cause ocular irritation. So, we restrict our formulation selection upto the Smix concentration of 35% from the selected phase diagram. Moreover at these Smix ratios the area of NE isotropic region was comparatively small.
Based on these set principal, four Smix ratios 1:0 (A1, A2), 1:1 (B1, B2), 1:2 (C1, C2), 2:1 (D1, D2) and 3:1 (E1, E2) were selected for the thermodynamic stability testing. All these DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 181
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
selected formulations have equal Smix concentration i.e 30% and 35% for their first and second formulations respectively. 6.4.4. Thermodynamic stability testing of drug loaded nanoemulsions
Nanoemulsions are thermodynamically stable systems and are formed at a particular concentration of oil, surfactant and water, with no phase separation, creaming or cracking. It is the thermo-stability which differentiates nano or microemulsions from emulsions that have kinetic stability and will eventually phase separate (Lawrence and Rees, 2000). Thus, the selected formulations were subjected to different thermodynamic stability by using heating cooling cycle, centrifugation and freeze thaw cycle stress tests. Those formulations, which survived thermodynamic stability tests, were taken for characterization with different physiochemical attributes. Table 6.20 given here showed the result of thermodynamic stability testing of drug loaded nanoemulsions. Table 6.20: Thermodynamic stability testing result of different selected nanoemulsion formulations Formulation with
Freeze thaw
Centrifugation
Heating
Inference
Smix ratio
cycle
studies
cooling cycle
A1 (1:0)
x
x
x
Failed
A2 (1:0)
x
x
x
Failed
B1 (1:1)
√
√
√
Passed
B2 (1:1)
√
√
√
Passed
C1 (1:2)
√
√
√
Passed
C2 (1:2)
√
√
√
Passed
D1 (2:1)
√
√
√
Passed
D2 (2:1)
√
√
√
Passed
E1 (3:1)
√
√
√
Passed
E2 (3:1)
√
√
√
Passed
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 182
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Results showed that nanoemulsion of Smix ratio 1:0 (A1 and A2) does not tolerated any stage of stability testing. Absence of cosurfactant which is required to create a suitable HLB value and stable flexible film for the stable NE system may be the rationale behind the instability of the NE of Smix ratio of 1:0 (V/V). 6.4.5. Preparation and assessment of mucoadhesive strength of chitosan solutions
The optimized chitosan concentration (1% w/v) of chitosan solution showing the strongest and desirable mucoadhesion (0.153N) among the test concentration (chapter 5.3) was selected for imparting the mucoadhesive characteristic in the optimized nanoemulsion (B1). 6.4.6. Characterization of non mucoadhesive and mucoadhesive nanoemulsions
In this work, the influence of concentration of NE components on the characteristics of NE was studied. The NEs and mucoadhesive were colloidal nano-dispersions as determined by TEM (figure 6.18 A and B). The NEs were seems to have spherical drug loaded globules that is uniformly distributed. Mucoadhesive NE (CH-B1) showed increased in size of the droplets that may be due to the adsorption and interaction of chitosan with the oleic acid and surfactant of the interface.
Figure 6.18: TEM microphotograph of CYA loaded nanoemulsion by TEM A) formulation B1 B) formulation CH-B1 (mucoadhesive nanoemulsion) (100,000×). DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 183
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Globules size distribution profile obtained from Zetasizer (Nano-ZS, Malvern Instruments, UK) for the optimized formulation having the smallest globular size is illustrated here in figure 6.19.
Figure 6.19: Globule size distribution of CYA loaded nanoemulsion before and after CH addition; A) formulation B1 B) formulation CH-B1. Composition of selected nanoemulsion formulations and their different characterization parameters vis. Droplet size distribution, zeta potential and viscosity are presented in table 6.21. Mean droplet size of formulation A1, A2 (A: 1:1), B1, B2 (B; 1:2) and C1, C2 (C: 2:1) were 36.10±1.97nm, 39.02±1.46nm, 18.92±1.03nm, 23.05±1.17nm, 42.30±3.30nm and 55.55±3.50nm respectively. Their zeta potential were varied from -14.3± 2.53mV – (31.3±1.54) mV. The viscosities of the formulations are low as expected for the o/w type nanoemulsion. The viscosities of the formulations (A1-C2) were varied from 29.35±1.92mP 132.67±3.54mP. The lowest viscosity was found for the formulation B1 (Smix; 1:2) which is 29.35±1.92mP.
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 184
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Table 6.21: Selected Nanoemulsions, mucoadhesive nanoemulsion formulation and their characterization parameters Formulation
Percent w/w of
code
components
Characterisation parameters
Oil
Smix
Aqueous
Mean
Zeta
Viscosity
Maximum
(%)
(%)
phase
Droplet
Potential
(mP±SD)
Drug
(%)
Size
(mV±SD)
Release
(nm± SD)
(%±SD)
A1 (1:1)
5.0
30
65
36.10±1.97
-22.8±0.31
61.00±2.40
89.7±1.2
A2 (1:1)
7.0
35
58
39.02±1.46
-31.3±1.54
73.40±2.95
87.54±2.1
B1 (1:2)
4.0
30
66
18.92±1.03
-14.3± 2.53
29.35±1.92
99.10±1.9
B2 (1:2)
6.0
35
59
23.05±1.17
-19.7± 2.72
37.30±2.67
98.3±2.8
C1 (2:1)
4.0
30
66
42.30±3.30
-18.0± 1.68
98.67±2.13
78.31±3.1
C2 (2:1)
7.0
35
58
55.55±3.50
-22.8±0.31
132.67±3.54
72.98±1.8
CH-B1
4.0
30
66*
41.70±1.15
+37.2±1.54
52.91±1.92
99.49±1.5
Values of polydispersity index (PI), which is a measure of uniformity of droplet size within the formulation, were also calculated. All the NE formulations exhibited a narrow size distribution (PI < 0.181). The results of particle size analysis were in agreement with the droplet size measured by TEM photograph. In case mucoadhesive nanoemulsion (CH-B1), there were increased in the droplet size (41.70±1.15nm) and zeta potential was positive (+37.2±1.54mV). The value of zeta potential clearly favour here that the selected formulation and the mucoadhesive CH-B1 having good dispersion stability due to fair charge repulsion. It is hypothetically described that at the optimum Smix ratio (1:2 for present study) the Transcutol P was exactly inserted into the cavities between the tween 20 molecules, causing DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 185
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
the interfacial film to condense and stabilize, resulting in smallest droplet diameters (18.92±1.03) with lowest polydispersity value (0.125 ± 0.05). In addition, particle size analysis revealed that with increase in oil concentration the droplet size of NE increases, irrespective of the Smix ratio. Large droplet size of oil rich formulations could be attributed to the fact that the higher concentration of Smix is required to solubilise the oil phase in the aqueous phase resulting an increase in size (Chen et al., 2006). As a result of viscosity measurements, a similar behavior, as for droplet size was obtained. Viscosity of all the NE formulations was very low as expected for o/w emulsion. When formulations with different Smix ratios were compared, the minimum viscosity values were obtained for B1 formulations (29.35±1.92mP). The low viscosity may be due to the presence of low amount of tween 20 (a fatty acid polyhydric alcohol ester having high intrinsic viscosity) compared to Transcutol P (a short chain alcohol having low intrinsic viscosity) (Akhter et al., 2008). All the drug free or drug loaded NE formulations had pH values ranging from 6.7 to 6.81, favourable for topical ocular application. It was observed that incorporation of drug did not significantly affect the pH values of NEs. 6.4.7. In-vitro CYA Release Study
The release profile of the selected NE formulations (A1-C2), mucoadhesive NE (CH-B1) and control formulations (Smix and oil) are presented here in figure 6.20. The maximum percentage of CYA release for the tested NE and mucoadhesive NE (CH-B1) are presented in Table 6.12.
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 186
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Figure 6.20: % drug release Vs time profile of selected formulations and controls for the period of 12hrs. As expected for the NEs, fast drug release behaviour were observed due to the enhanced dissolution and spreading of the oil micellar solubilisation due to the optimized bend of surfactant and cosurfactant that developed the optimum HLB. Maximum percentage release of CYA after 12h was found to be highest (99.10±1.9nm) for B1 (Smix: 1:2). Moreover, chitosan coated formulation (CH-B1) also showed the similar release profile having the equivalent maximum percentage of drug release (99.49±1.5). Although, all the formulations contain equal drug amount, low release rate as observed for controls, provided that concentration gradient is not a single factor affecting the rate of permeation.
Enhanced drug release with NEs could be explained on basis of the several mechanisms:
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 187
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
1) Continuous and spontaneous fluctuating stable interfaces of NE enable high drug mobility and might enhance the drug diffusion process. 2) High solubilisation of CYA in NE resulting in high thermodynamic activity of the drug providing significant driving force for its release. 6.4.8. In-vivo study
6.4.8.1. Ocular retention study by Gamma scientigraphy Gamma scintigraphy is a well-established technique for in vivo evaluation of the ocular retention study of ophthalmic drug delivery. The precorneal clearance of the optimized CYA non mucoadhesive (B1) and CH-coated mucoadhesive NEs formulation (CH-B1) were monitored using γ-scientigraphy. CYA mucoadhesive NEs formulation (CH-B1) and non mucoadhesive formulation (B1) was radiolabeled with radionuclide Tc-99m. They were instantaneously labeled with Tecnetium99m with good labeling efficiency (≥ 95%) and less number of colloids (≤ 5%). After administration of the radio labeled ophthalmic formulation, a good spreading was observed over the entire precorneal area. Identifying ROIs and defining them as ocular allowed for monitoring the transit of the formulation, and subsequently, quantifying the remaining activity in these regions at different time points. Gamma scintigraphic dynamic images of whole-body of rabbit for first 30 minutes after administration of the formulations and the control and the radioactivity remaining in the ROI on dynamic images (radioactivity remaining Vs time profile) over period of 30 min are illustrated here in figure 6.21 and figure 6.22 respectively.
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 188
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Figure 6.21: Gamma scintigraphic dynamic images of whole-body of rabbit for first 30 minutes (30 sec per frame) after 5 minutes of administration CH-B1.
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 189
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Figure 6.22: Gamma scintigraphic dynamic images of whole-body of rabbit for first 30 minutes (30 sec per frame) after 5 minutes of administration B1.
Percentage of radioactivity remaining at different time point, Log % activity remained, AUC of activity of CYA mucoadhesive NEs formulation (CH-B1) as compared to non mucoadhesive formulation (B1) is presented in table 6.22 and table 6.23.
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 190
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
Table 6.22: % Activity remaining, AUC0→30 min for CYA mucoadhesive NEs formulation (CH-B1) as compared to non mucoadhesive formulation (B1) after topical application onto the rabbit eye CH-B1 Image No.
B1
Time (sec)
Counts
Counts/sec
AUC
%Activity Remaining
0
0
0
0
0
0
1
5
380
76
190
100
2
10
374
74.8
377
98.421
3
15
372
74.4
373
4
20
363
72.6
5
25
357
6
30
7
35
8
Log % AR
Counts
Counts/sec
AUC
%Activity Remaining
Log % AR
0
0
0
0
2
130
26
65
100
2
1.9931
124
24.8
127
95.385
1.97948
97.895
1.9908
121
24.2
122.5
93.077
1.96884
367.5
95.526
1.9801
117
23.4
119
90.000
1.95424
71.4
360
93.947
1.9729
114
22.8
115.5
87.692
1.94296
357
71.4
357
93.947
1.9729
112
22.4
113
86.154
1.93527
356
71.2
356.5
93.684
1.9717
111
22.2
111.5
85.385
1.93138
40
352
70.4
354
92.632
1.9668
110
22
110.5
84.615
1.92745
9
45
350
70
351
92.105
1.9643
109
21.8
109.5
83.846
1.92348
10
50
349
69.8
349.5
91.842
1.9630
107
21.4
108
82.308
1.91544
11
55
349
69.8
349
91.842
1.9630
107
21.4
107
82.308
1.91544
12
60
346
69.2
347.5
91.053
1.9593
106
21.2
106.5
81.538
1.91136
13
65
345
69
345.5
90.789
1.9580
105
21
105.5
80.769
1.90725
14
70
341
68.2
343
89.737
1.9530
104
20.8
104.5
80.000
1.90309
15
75
340
68
340.5
89.474
1.9517
103
20.6
103.5
79.231
1.89889
16
80
340
68
340
89.474
1.9517
102
20.4
102.5
78.462
1.89466
17
85
338
67.6
339
88.947
1.9491
100
20
101
76.923
1.88606
18
90
336
67.2
337
88.421
1.9466
99
19.8
99.5
76.154
1.88169
19
95
335
67
335.5
88.158
1.9453
99
19.8
99
76.154
1.88169
20
100
327
65.4
331
86.053
1.9348
98
19.6
98.5
75.385
1.87728
21
105
327
65.4
327
86.053
1.9348
98
19.6
98
75.385
1.87728
22
110
326
65.2
326.5
85.789
1.9334
98
19.6
98
75.385
1.87728
23
115
321
64.2
323.5
84.474
1.9267
97
19.4
97.5
74.615
1.87283
24
120
320
64
320.5
84.211
1.9254
96
19.2
96.5
73.846
1.86833
25
125
319
63.8
319.5
83.947
1.9240
96
19.2
96
73.846
1.86833
26
130
319
63.8
319
83.947
1.9240
96
19.2
96
73.846
1.86833
27
135
316
63.2
317.5
83.158
1.9199
95
19
95.5
73.077
1.86378
28
140
316
63.2
316
83.158
1.9199
95
19
95
73.077
1.86378
29
145
315
63
315.5
82.895
1.9185
93
18.6
94
71.538
1.85454
30
150
315
63
315
82.895
1.9185
93
18.6
93
71.538
1.85454
31
155
312
62.4
313.5
82.105
1.9144
87
17.4
90
66.923
1.82558
32
160
311
62.2
311.5
81.842
1.9130
86
17.2
86.5
66.154
1.82056
33
165
305
61
308
80.263
1.9045
85
17
85.5
65.385
1.81548
34
170
303
60.6
304
79.737
1.9017
83
16.6
84
63.846
1.80513
35
175
303
60.6
303
79.737
1.9017
80
16
81.5
61.538
1.78915
36
180
297
59.4
300
78.158
1.8930
78
15.6
79
60.000
1.77815
37
190
592
59.2
593
77.895
1.8915
154
15.4
155
59.231
1.77255
38
200
591
59.1
591.5
77.763
1.8908
152
15.2
153
58.462
1.76687
39
210
593
59.3
592
78.026
1.8922
151
15.1
151.5
58.077
1.76400
40
220
589
58.9
591
77.500
1.8893
148
14.8
149.5
56.923
1.75529
41
230
587
58.7
588
77.237
1.8878
146
14.6
147
56.154
1.74938
42
240
585
58.5
586
76.974
1.8863
147
14.7
146.5
56.538
1.75234
43
250
583
58.3
584
76.711
1.8849
144
14.4
145.5
55.385
1.74339
44
260
582
58.2
582.5
76.579
1.8841
142
14.2
143
54.615
1.73731
45
270
580
58
581
76.316
1.8826
141
14.1
141.5
54.231
1.73425
46
280
581
58.1
580.5
76.447
1.8834
139
13.9
140
53.462
1.72804
DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM Jamia Hamdard 191
DES Chapter 6
Cyclosporine A Nanoemulsion Formulation
47
290
579
57.9
580
76.184
1.8819
137
13.7
138
52.692
1.72175
48
300
575
57.5
577
75.658
1.8789
135
13.5
136
51.923
1.71536
49
320
1148
57.4
1149
75.526
1.8781
267
13.35
268.5
51.346
1.71051
50
340
1147
57.35
1147.5
75.461
1.8777
265
13.25
266
50.962
1.70724
51
360
1145
57.25
1146
75.329
1.8770
262
13.1
263.5
50.385
1.70230
52
380
1146
57.3
1145.5
75.395
1.8773
261
13.05
261.5
50.192
1.70064
53
400
1143
57.15
1144.5
75.197
1.8762
258
12.9
259.5
49.615
1.69562
54
420
1141
57.05
1142
75.066
1.8754
254
12.7
256
48.846
1.68883
55
440
1138
56.9
1139.5
74.868
1.8743
252
12.6
253
48.462
1.68540
56
460
1135
56.75
1136.5
74.671
1.8732
250
12.5
251
48.077
1.68194
57
480
1133
56.65
1134
74.539
1.8724
251
12.55
250.5
48.269
1.68367
58
500
1130
56.5
1131.5
74.342
1.8712
247
12.35
249
47.500
1.67669
59
520
1129
56.45
1129.5
74.276
1.8709
245
12.25
246
47.115
1.67316
60
540
1131
56.55
1130
74.408
1.8716
242
12.1
243.5
46.538
1.66781
AUC0-t =
69197.0
AUC0-t =
11833.5
As expected, the drainage of the CYA mucoadhesive NEs formulation was fast, and it was detectable in the stomach and rectum of the rabbit at the end of the monitoring period. The poor performance of the CYA NEs (B1) during the drainage study could be attributed to lack of mucoadhesion with the cornea (Akhter et al., 2011). In contrast, the CYA mucoadhesive NEs formulation system (CH-B1) was retained on the ocular surface significantly longer (P